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Atypical chemokine receptors (ACKRs) are regulators of leukocyte traffic, 36 
inflammation and immunity. ACKR2 is a scavenger for most inflammatory CC 37 
chemokines and is a negative regulator of inflammation. Here we report that ACKR2 38 
is expressed in hematopoietic precursors and downregulated during myeloid 39 
differentiation. Genetic inactivation of ACKR2 results in increased levels of 40 
inflammatory chemokine receptors and release from the bone marrow of neutrophils 41 
with increased anti-metastatic activity. In a model of NeuT-driven primary mammary 42 
carcinogenesis ACKR2 deficiency is associated with increased primary tumor growth 43 
and protection against metastasis. ACKR2-deficiency results in neutrophil-mediated 44 
protection against metastasis in mice orthotopically transplanted with 4T1 mammary 45 
carcinoma and intravenously injected with B16F10 melanoma cell lines. Thus, 46 
ACKR2 is a key regulator (checkpoint) of mouse myeloid differentiation and function 47 
and its targeting unleashes the anti-metastatic activity of neutrophils in mice. 48 






Chemokines are key components of tumor microenviroment1,2. Production of 52 
chemokines sustains unresolving chronic inflammation which promotes 53 
carcinogenesis. Moreover, oncogene activation drives chemokine production and 54 
leukocyte recruitment in tumors epidemiologically unrelated to inflammatory 55 
conditions3.  56 
The repertoire of chemokines produced in the context of neoplastic tissues 57 
shapes the leukocyte infiltrate1,2. For instance, CCL2 and CXCL8 and related CC and 58 
CXC chemokines, are major determinants of macrophage and neutrophil recruitment, 59 
respectively. CCL17 and CCL22 have been associated with recruitment of Th2 and 60 
Treg cells which tame effective antitumor immunity. Conversely CXCL10 driven 61 
recruitment of CD8 T cells and Th1 cells is a driver of antitumor resistance1,2,4. 62 
Chemokine and chemokine receptors are important determinants of invasion 63 
and metastasis5. For instance, the chemokine repertoire expressed by tumor cells 64 
impacts on secondary seeding at distant sites such as the brain or lymph nodes6. 65 
Moreover inflammatory chemokines precondition the metastatic niche and drive 66 
tumor cell seeding at sites of secondary localization7. 67 
Canonical chemokine receptors are seven transmembrane G protein coupled 68 
receptors. Mature leukocyte subsets express distinct repertoires of signaling 69 
chemokine receptors8. Moreover, the chemokine system includes a limited set (four) 70 
of atypical chemokine receptors (ACKR). ACKRs bind a broad panel of inflammatory 71 
(ACKR1 and ACKR2) or homeostatic (ACKR3 and ACKR4) chemokines and regulate 72 
ligand availability by acting as decoys, scavengers, transporters or depot9-11.  73 
ACKR2 (previously known as D6) acts as a decoy and scavenger for most 74 
inflammatory CC chemokines and is expressed by lymphatic endothelial cells, 75 
trophoblasts in the placenta and some leukocytes such as innate B cells and alveolar 76 
macrophages11. In line with its scavenger function, ACKR2 is a negative regulator of 77 
inflammation at different anatomical sites11. Inflammation is a key component of the 78 
tumor microenvironment12. Accordingly, genetic inactivation of ACKR2 unleashes 79 
tumor promoting inflammation in the skin and GI tract13-15. Moreover, downregulation 80 
of ACKR2 in transformed cells has been associated with tumor progression and 81 
oncogene activation in Kaposi sarcoma16-18. 82 




previous carcinogenesis results13,14, in an oncogene driven mammary carcinoma 84 
model we found that ACKR2-deficient mice show enhanced tumor growth at the 85 
primary tumor site. In contrast, ACKR2 gene-targeted mice are protected against 86 
metastasis. This unexpected finding, extended to transplanted tumors, prompted a 87 
dissection of underlying mechanisms. We found that ACKR2 is expressed in 88 
hematopoietic progenitor cells (HPCs) and that it serves as a key regulator 89 
(checkpoint) of myeloid differentiation and function. Targeting ACKR2 unleashed the 90 
anti-metastatic potential of neutrophils. 91 






Ackr2-/- mice are protected against tumor metastasis 95 
 In order to extend previous studies on ACKR2 in carcinogenesis, we crossed 96 
Balb/c Ackr2-/- mice with Balb/c NeuT mice, which overexpress the rat HER2 (Neu) 97 
oncogene under the mouse mammary tumor virus (MMTV) promoter and 98 
spontaneously develop mammary carcinomas closely recapitulating human breast 99 
carcinogenesis19. We followed primary tumor development measuring time of 100 
appearance and volume, and found that in NeuT/Ackr2-/- mice tumor masses in 101 
mammary glands developed earlier (Supplementary Fig. 1a) and reached higher 102 
volumes as compared to NeuT/Ackr2+/+ mice (Fig. 1a). This result is in accordance 103 
with previous reports showing that ACKR2 genetic deficiency results in increased 104 
growth of primary tumors13,14. Unexpectedly, lung analysis revealed less metastatic 105 
lesions in NeuT/Ackr2-/- mice as compared to NeuT/Ackr2+/+ mice (Fig. 1b and 1c). 106 
 In an effort to strengthen and extend these findings, the transplanted tumor 107 
lines 4T1 (mammary carcinoma) and B16F10 (melanoma), were used. 4T1 tumor 108 
cells were transplanted orthotopically, whereas B16F10 melanoma cells were 109 
injected i.v. in a classic “artificial” hematogenous metastasis model (see below).  110 
 When 4T1 cells were injected into the mammary glands of WT and Ackr2-/- 111 
mice, no difference in primary tumor growth was detected (Fig. 1d), but again the 112 
number of spontaneous lung metastasis was significantly lower in Ackr2-/- mice (Fig. 113 
1e and 1f). Since 4T1 cells expressed little or no Ackr2, before and after in vivo 114 
growth (Supplementary Fig. 1B), these results suggested that the regulatory function 115 
of ACKR2 on metastasis is not cancer cell-intrinsic. 116 
 In order to understand which cells protect mice from metastasis, BM chimeric 117 
mice were orthotopically injected with 4T1 cells. Mice were protected from metastasis 118 
only when Ackr2 was genetically inactivated in the hematopoietic compartment 119 
(Supplementary Fig. 1c), demonstrating that protection phenotype was due to 120 
hematopoietic expression of ACKR2. 121 
 122 
Increased myeloid cell mobilization in Ackr2-/- mice 123 
 The two breast cancer models used in our experiments are known to induce 124 
expansion and mobilization of myeloid cells, which then promote tumor growth20,21. 125 




which in contrast is unable to induce myeloid cell expansion and is less 127 
metastatic22,23, we did not find any difference in the number of metastatic lesions 128 
between WT and Ackr2-/- mice (Fig. 1f). We therefore focused on effects of Ackr2 129 
genetic inactivation on the myeloid compartment of tumor-bearing mice as a potential 130 
mechanism of protection from metastasis.  131 
NeuT/Ackr2+/+ mice, at 25 weeks of age, have an increased number of circulating 132 
Ly6Chigh monocytes and Ly6G+ neutrophils (Fig. 2a and 2b, respectively; gating 133 
strategy in Supplementary Fig. 2a) compared with Balb/c WT mice20,21. As we 134 
previously reported24, Ackr2-/- mice have increased number of circulating Ly6Chigh 135 
monocytes (Fig. 2a), while no significant difference was found in the number of 136 
neutrophils (Fig. 2b) compared to WT mice. At 25 weeks of age, NeuT/Ackr2-/- mice 137 
presented a further significant increase of blood monocytes and neutrophils (Fig. 2a 138 
and 2b) compared to Ackr2-/- and NeuT/Ackr2+/+, indicating that the lack of Ackr2 was 139 
a further driver of tumor-induced myelopoiesis and/or BM release of myeloid cells. 140 
 Increased number of inflammatory monocytes and neutrophils, but not alveolar 141 
or interstitial macrophages, were also detected in the lungs of NeuT/Ackr2-/- as 142 
compared to NeuT/Ackr2+/+ mice (Fig. 2c and Supplementary Fig. 2b for the gating 143 
strategy), while in basal conditions no difference was found between leukocyte 144 
infiltrate in the lung of WT and Ackr2-/- mice (Supplementary Fig. 2c). A higher 145 
number of Ly6G+ neutrophils in the parenchyma of NeuT/Ackr2-/- lungs compared to 146 
NeuT/Ackr2+/+ mice was also found by immunohistochemistry, confirming the flow 147 
cytometry data (Fig. 2d and 2e). Similar results were obtained analyzing blood and 148 
lungs of WT and Ackr2-/- mice orthotopically injected with 4T1 cells (Supplementary 149 
Fig. 2d and 2e, respectively). In these mice, analysis of myeloid cells in the bone 150 
marrow (BM) 14 days after tumor injection, showed a reduced number of monocytes 151 
and neutrophils in Ackr2-/- compared to WT mice (Fig. 2f). These results indicate that, 152 
in tumor conditions, Ackr2-/- mice show enhanced release of myeloid cells from BM, 153 
which then accumulate in the blood and lungs. 154 
 155 
Increased chemokine-induced mobilization in Ackr2-/- mice 156 
To investigate the role of ACKR2 in myeloid cells egress from the BM, we 157 
performed leukocyte mobilization experiments. As previously reported and as shown 158 
in Figure 3a, under homeostatic conditions, ACKR2-deficient mice have increased 159 




and a concomitant decrease in the frequency of the same cells in the BM (Fig. 3c), 161 
whereas they showed similar number of circulating and BM neutrophils24 (Fig 3b and 162 
3d). After injection of CCL3L1, an ACKR2 ligand known to induce rapid mobilization 163 
of both neutrophils and monocytes25, Ackr2-/- mice showed a significant higher 164 
number of circulating monocytes and neutrophils compared to WT littermates (Fig. 3a 165 
and 3b, respectively). Concomitantly, the decrease in monocytes and neutrophils in 166 
the BM caused by CCL3L1 injection was more pronounced in Ackr2-/- animals (Fig. 167 
3c and 3d, respectively). 168 
 BM chimera experiments showed that both WT and Ackr2-/- hosts when 169 
transplanted with Ackr2-/-, but not WT, hematopoietic cells had an increased number 170 
of circulating monocytes and neutrophils (Fig. 3e and f; Supplementary Fig. 3a and 171 
3b) and higher number of monocytes and neutrophils infiltrating the lung 172 
(Supplementary Fig. 3c and 3d). These results demonstrated that the increased 173 
mobilization of monocytes and neutrophils induced by CCL3L1 injection was caused 174 
by the absence of ACKR2 in the hematopoietic compartment.  175 
Finally, in order to understand whether there is a different localization of 176 
leukocytes in the BM sinusoids of ACKR2 deficient mice, we performed in vivo 177 
labelling experiments of monocytes with a 2-minute pulse of anti-Ly6C-PE antibody 178 
as previously described26. In ACKR2-deficient BM sinusoids there was a significant 179 
higher percentage of monocytes located in this vascular compartment after 180 
chemokine induced mobilization compared to WT controls (Supplementary Fig. 3e 181 
and 3f). 182 
 183 
Neutrophils protect Ackr2-/- mice from metastasis 184 
 To investigate the relevance of the increased myeloid cell mobilization found in 185 
Ackr2-/- mice in the metastatic process, the B16F10 melanoma cell line was injected 186 
i.v. in a classic “artificial” hematogenous metastasis model. In this experimental 187 
setting, Ackr2-/- mice showed increased number of circulating neutrophils while no 188 
differences were found in the number of circulating monocytes, T and B lymphocytes 189 
compared to WT mice (Supplementary Fig. 4a). Also in this model, there was a 190 
significant reduction in the metastatic ratio in the lungs of ACKR2-deficient hosts 191 
compared to WT animals (Fig. 4a). In order to understand which cells were 192 
responsible for metastasis protection, we performed depletion experiments by using 193 




monoclonal antibody significantly decreased the number of metastasis in WT mice, 195 
but did not reverse the protection observed in Ackr2-/- mice (Supplementary Fig. 4b). 196 
We then performed neutrophil depletion with an α-Ly6G monoclonal antibody. 197 
Neutrophil depletion caused a reduction in metastasis in WT mice while an increase 198 
in metastatic ratio was observed in Ackr2-/- mice (Fig. 4b). The protective role of 199 
neutrophils in Ackr2-/- mice was also demonstrated by performing depletion 200 
experiments with the ortotopically transplanted 4T1 tumor line. Also in this model, 201 
neutrophil depletion reduced the metastatic ratio in WT mice, while it increased 202 
metastasis in Ackr2-/- hosts (Fig. 4c). Finally, since ACKR2 was reported to be 203 
expressed by B lymphocytes27, we performed B lymphocyte depletion using an α-204 
CD20 monoclonal antibody with no rescue of the metastasis phenotype associated 205 
with ACKR2 deficiency (Supplementary Fig. 4c). 206 
 The role of Ackr2-/- neutrophils in protection against metastasis was further 207 
investigated by adoptive cell transfer experiment. Transfer of Ackr2-/-, but not WT, 208 
neutrophils into WT tumor-bearing mice significantly reduced the metastatic ratio 209 
(Fig. 4d) to values comparable to those observed in Ackr2-/- tumor-bearing mice. 210 
 211 
Increased tumor-killing activity of Ackr2-/- neutrophils 212 
 As depletion and adoptive transfer experiments clearly pointed to neutrophils as 213 
the key elements responsible for protection against metastasis observed in the 214 
absence of ACKR2, we evaluated their reactive oxygen species (ROS) production, 215 
one of the main mechanism of tumor cell killing. Neutrophils from B16F10-bearing 216 
Ackr2-/- animals produced significantly higher amounts of ROS compared to WT mice 217 
(Fig. 5a). Similar results were obtained analyzing neutrophils in 4T1-bearing WT and 218 
Ackr2-/- mice (Supplementary Fig. 5a). 219 
 Ackr2-/- neutrophils also showed a significant increase in transcript levels of the 220 
chemokine receptors Ccr1, Ccr2 and Ccr5, but not Cxcr4 (Fig. 5b), while expression 221 
levels of other genes associated with neutrophils activation, including Tnf-α, Alox5, 222 
Vegf-a, and Arg1, were not different between WT and Ackr2-/- cells (Fig. 5c). 223 
Adoptive transfer experiments demonstrated that Ackr2-/- neutrophils display 224 
increased recruitment to the lung compared to WT neutrophils with a concomitant 225 
reduction of their number in the blood (Fig. 5d and 5e, respectively). 226 
 Chemokines were reported to control not only neutrophil recruitment to 227 




production28. We therefore examined whether the increased levels of CC chemokine 229 
receptors found on Ackr2-/- neutrophils could result in increased ROS production. 230 
Compared to WT cells, Ackr2-/- neutrophils produced more ROS already under 231 
resting conditions and even more so after stimulation with the CCR2 ligand CCL2 232 
(Fig. 5f).  233 
 In order to assess the functional relevance of this observation, circulating 234 
neutrophils were isolated from tumor-bearing mice and evaluated for their ability to 235 
kill tumor cells in vitro. Neutrophils obtained from Ackr2-/- mice displayed an 236 
increased tumor killing activity (Fig. 5g) compared to cells isolated from WT mice. 237 
The killing activity of both WT and Ackr2-/- neutrophils was partially reversed by the 238 
ROS inhibitor apocynin. Similar results were obtained with neutrophils isolated from 239 
resting WT and Ackr2-/- mice (Supplementary Fig. 5b).  240 
 Collectively, these results suggest that neutrophil activation during tumor 241 
progression is constrained by ACKR2, which impinges on their expression of CC 242 
chemokine receptors and inhibits their migration to the lung and their ability to 243 
generate ROS, key mediators of neutrophil antitumoral potential29,30. 244 
 245 
Ackr2 is expressed by HPCs and controls myelopioesis 246 
 Results with BM chimeras demonstrated that ACKR2 expression by 247 
hematopoietic cells was responsible for the more pronounced neutrophil mobilization 248 
(Fig. 3e and 3f) and for protection against metastasis found in Ackr2-/- mice 249 
(Supplementary Fig. 1c). As Ackr2 mRNA expression was very low in neutrophils 250 
(Fig. 6b), we traced its expression on sorted myeloid lineage hematopoietic 251 
precursors (gating strategy Supplementary Fig. 6a). Ackr2 transcript level was 252 
highest in Linneg/Sca-1+/cKit+ (LSK) cells, and was then downregulated in the more 253 
mature common myeloid progenitors (CMP; Linneg/Sca-1-/cKit+/CD34+/FcγRII/IIIint) 254 
and granulocytes-monocytes progenitors (GMP; Linneg/Sca-1-255 
/cKit+/CD34+/FcγRII/IIIhigh) (Fig. 6a and b). Thus, the most immature progenitors have 256 
the highest level of Ackr2 expression, which then declines during the myeloid 257 
differentiation, showing an opposite behavior as compared to CCR2, whose 258 
expression is upregulated during maturation31 (Fig. 6c). 259 
 When we performed expression analysis of other chemokine receptors, we 260 
found that, similarly to neutrophils, LSK, CMP and GMP isolated from Ackr2-/- mice 261 




Supplementary Fig. 6b and 6c). FACS analysis confirmed an increased expression of 263 
CCR2 in Ackr2-/- LSK, CMP and GMP cells and revealed that this was restricted to 264 
the myeloid lineage, as no detectable levels of CCR2 were observed in both WT and 265 
Ackr2-/- megakaryocyte-erythroid progenitors (MEP; Linneg/Sca-1-/cKit+/CD34-266 
/FcγRII/III-) (Fig. 6d). On the other hand, we did not find differences in CXCR4 mRNA 267 
and protein expression in WT and Ackr2-/- HPCs (Fig. 6e and 6f, respectively). These 268 
results indicate that ACKR2 is expressed by HPCs and controls the expression of 269 
inflammatory CC chemokine receptors known to be involved in myeloid cell release 270 
from BM. 271 
 WT and Ackr2-/- BM did not differ in the absolute number of LSK and CMP, 272 
while a trend of increase was observed in the number of GMP in the BM of Ackr2-/-273 
compared to WT mice (Supplementary Fig. 6d). In addition, no difference in the 274 
proliferation of hematopoietic progenitors (Supplementary Fig. 6e) and in the levels of 275 
the hematopoietic growth factor G-CSF (Supplementary Fig. 6f) was found 276 
comparing resting and tumor-bearing WT and Ackr2-/- mice. 277 
 However, LSK cells sorted from BM Ackr2-/-  and cultured in vitro had increased 278 
expression of the myeloid differentiation markers Ly6G, Ly6C, and CD11b, as 279 
compared to their WT counterparts (Fig. 6g to 6i, respectively). Conversely, induction 280 
of ACKR2 high expression levels by transfection in the human promyelocytic cell line 281 
HL-60, which express low levels of ACKR2 (Supplementary Fig. 6g and 6h), resulted 282 
in a significant reduction of CCR2 and CD11b expression, while no change in 283 
CXCR4 levels was detectable (Fig. 6j). The increased maturation of neutrophils was 284 
also supported by in vivo experiments with a BrdU analog32. Indeed, in the blood of 285 
Ackr2-/- mice there were more mature neutrophils compared to WT mice 286 
(Supplementary Fig. 6i). 287 
 Collectively, these data indicate that Ackr2 genetic inactivation in early 288 
hematopoietic precursors results in an accelerated maturation rate of neutrophils, 289 
which are more efficiently mobilized by inflammatory chemokines and efficiently 290 
recruited to metastatic lesions, where they perform enhanced anti-metastatic activity. 291 
ACKR2 in hematopoietic precursors thus operates as a checkpoint for myeloid cell 292 
mobilization and effector functions, and its targeting may pave the way to innovative 293 






Chemokines are essential mediators of cancer-related inflammation. 297 
Chemokines and chemokine receptors are downstream of oncogene activation and 298 
inactivation of oncosuppressor genes, as illustrated by CXCR4 and the VHL 299 
pathway1,33. Inflammatory chemokines contribute to shaping the landscape of 300 
immunity in cancer by recruiting tumor promoting myeloid cells, polarized Th2 cells 301 
and T reg cells and by promoting  M2-like skewing of TAM1. 302 
Consistently with this general picture, inactivation of ACKR2, a decoy and 303 
scavenger receptor for inflammatory CC chemokines, was associated with enhanced 304 
carcinogenesis in the skin and GI tract13,14. Conversely, downregulation of ACKR2 305 
driven by Kras activation is associated with tumor progression in human Kaposi’s 306 
sarcoma and  in a mouse vascular tumor model16. Tuning of monocyte recruitment 307 
underlies the regulatory function of ACKR2 in tumor progression15. 308 
In agreement with this set of previous data we found that in a model of primary 309 
mammary carcinogenesis driven by Her2, an oncogene involved in human breast 310 
cancer, ACKR2 deficiency was associated with accelerated appearance and growth 311 
of primary lesions. Given the tumor promoting function of TAM in murine and human 312 
breast cancer7,34,35, it is reasonable to assume that enhanced tumor growth was 313 
mediated by macrophages. Unexpectedly, in the same model, we found that ACKR2 314 
deficiency was associated with protection against metastasis, an observation in 315 
sharp contrast with the primary tumor phenotype. 316 
Protection against lung metastasis in ACKR2 deficient hosts was also 317 
observed in the 4T1 mammary carcinoma line transplanted orthotopically and in the 318 
classic B16F10 melanoma cell line injected intravenously. The unexpected finding of 319 
protection against metastasis prompted a dissection of underlying mechanisms 320 
taking advantage of transplanted tumor models. 321 
Several lines of evidence indicate that neutrophils mediate resistance to 322 
metastasis in ACKR2 deficient hosts. ACKR2 deficiency was associated with 323 
profound alterations in neutrophil phenotype and function. Indeed Ackr2-/- neutrophils 324 
had increased ROS production and cell-killing activity, a pattern that identifies mature 325 
or activated neutrophils32. Moreover, neutrophils lacking ACKR2 had increased 326 
expression of the chemokine receptors Ccr1, Ccr2 and Ccr5, a chemokine receptor 327 




pattern of chemokine receptors depending on their activation state36,37. IFN-γ the 329 
prototypic Th1 cytokine, upregulates the expression of the CC chemokine receptors 330 
CCR1 and CCR338 and inflammatory stimuli such as LPS induce CCR2 expression in 331 
neutrophils39. The expression of CC chemokine receptors by neutrophils is 332 
functionally relevant not only in terms of recruitment to the inflamed site but also in 333 
the activation of their effector functions such as respiratory burst, bacterial killing and 334 
anti-metastatic activity28,36,40. In line with these data Ackr2-deficient neutrophils 335 
showed increased recruitment to the lungs (Supplementary Fig. 3d) and increased 336 
tumor killing activity (Fig 5g) compared to WT neutrophils. 337 
The role of neutrophils in protection against metastasis was also demonstrated 338 
by depletion experiments. Neutrophil depletion rescued the phenotype of resistance 339 
to metastasis observed in ACKR2 deficient hosts. Interestingly, in ACKR2-competent 340 
mice neutrophil depletion resulted in reduced metastasis (Fig 4b and c), in line with 341 
several observations of neutrophil-mediated tumor promotion (see below). Finally, 342 
adoptive transfer of ACKR2-deficient neutrophils mediated resistance against 343 
metastasis (Fig 4d). Thus, unleashing neutrophil mediated resistance underlies 344 
protection against metastasis observed in ACKR2 deficient mice.  345 
The finding that ACKR2 expression was vanishingly low in mature neutrophils, 346 
raised the possibility of a regulatory function of this molecule upstream in 347 
hematopoiesis. We found that ACKR2 is expressed by HPCs and that it is 348 
downregulated during maturation in myeloid progenitors. Interestingly, ACKR2 was 349 
cloned in 1997 from the BM41 but its role and expression in this compartment has not 350 
been explored42. Here we found that Ackr2-/- HPCs, like Ackr2-/- neutrophils, express 351 
extremely high levels of the chemokine receptors CCR1, CCR2 and CCR5 and, when 352 
cultured with differentiating cytokines, acquire myeloid differentiation markers faster 353 
compared to WT counterparts. 354 
To directly assess the effect of ACKR2 on chemokine receptors in immature 355 
hematopoietic elements, the HL-60 cell line was used. Here ACKR2 downregulated 356 
the expression of CCR2 and of the integrin CD11b. ACKR2 induces a signal 357 
transduction cascade activating a β-arrestin dependent signaling that optimizes its 358 
chemokine scavenging activity43. It is likely that in HPCs β-arrestin signaling by 359 
ACKR2 negatively controls the expression of CC chemokine receptors by interfering 360 
with other signaling pathways or by activating mechanism of negative regulation as 361 




signaling by CXCR444 and ACKR4 inhibits the expression of CCR7, CCR9, CXCR5, 363 
and CXCR445. Our data are also consistent with previous published data reporting 364 
that ACKR2 regulates neutrophil migration towards inflammatory CC chemokines46. 365 
Neutrophils have emerged as important players in cancer-related 366 
inflammation. In general, several lines of evidence indicate that neutrophils are part 367 
of the inflammatory network which promotes tumor progression and metastasis47-49. 368 
In accordance with this line of evidence, we observed that neutrophil depletion using 369 
an α-Ly6G mAb resulted in decreased lung metastasis in the B16F10 and in the 4T1 370 
models (Fig. 4b and 4c). However, neutrophils can undergo functionally 371 
reprogramming in response to tumor and host derived signals48,49 and accordingly 372 
exert divergent influence on tumor growth50, a dichotomy mirrored by prognostic 373 
significance in different human cancers51. 374 
Here we report that ACKR2 expressed by hematopoietic progenitor cells is a 375 
key setpoint of neutrophil differentiation, mobilization and function (Supplementary 376 
Fig. 7). Targeting hematopoietic ACKR2 may pave the way to innovative therapeutic 377 
strategies unleashing myeloid cell-mediated protection against infection and cancer. 378 
 379 
MATERIALS AND METHODS 380 
 381 
Cell lines 382 
4T1 and 4T1-66cl4 cells (kindly provided by Dr Claudia Chiodoni, Department of 383 
Experimental Oncology and Molecular Medicine, Istituto Nazionale dei Tumori, 384 
Milano, Italy) were grown in DMEM (Lonza) supplemented with 10% FBS (Sigma), 385 
1% penicillin/streptomycin (Lonza), 1% L-glutamine (Lonza), 1% sodium pyruvate 386 
(Lonza), 1% Hepes (Lonza). B16-F10, kindly provided by Prof Massimiliano Mazzone 387 
(Vesalius Research Center, Leuven, Belgium), were grown in DMEM (Lonza) 388 
supplemented with 10% FBS (Sigma), 1% penicillin/streptomycin (Lonza), 1% L-389 
glutamine (Lonza). 4T1-luc from PerkinElmer were grown in RPMI 1640 (Lonza), 390 
10% FBS (Sigma), 1% penicillin/streptomycin (Lonza), 1% L-glutamine (Lonza), 1% 391 
sodium pyruvate (Lonza), 5.4 g/l glucose (Sigma). HL-60 were purchased from ATCC 392 
and grown in IMDM (Lonza), 20% FBS (Sigma), 1% Penicillin/Streptomycin (Lonza), 393 
1% L-glutamine (Lonza), 1% Sodium Pyruvate (Lonza), and transfected with pEGFP-394 
N1 ACKR2 or mock vector52 by using the Nucleofector Kits for HL60 (Lonza) 395 




mRNA analysis. Cells were tested for Mycoplasma and only Mycoplasma free cells 397 
were used. 398 
 399 
Animals 400 
Ackr2-/- mice were maintained on Balb/c and C57BL/6J genetic background. Balb/c 401 
WT and Ackr2-/- mice were crossed with NeuT mice (kindly donated by Professor 402 
Federica Cavallo, University of Turin, Italy). WT and WT CD45.1 mice were obtained 403 
from Charles River Laboratories (Calco, Italy) or were cohoused littermates. All 404 
colonies were housed and bred in the SPF animal facility at Humanitas Clinical and 405 
Research Center in individually ventilated cages. Mice used for experiments were 8 406 
to 12 weeks old. Procedures involving animals handling and care were conformed to 407 
protocols approved by the Humanitas Clinical and Research Center (Rozzano, Milan, 408 
Italy) in compliance with national (4D.L. N.116, G.U., suppl. 40, 18-2-1992) and 409 
international law and policies (EEC Council Directive 2010/63/EU, OJ L 276/33, 22-410 
09-2010; National Institutes of Health Guide for the Care and Use of Laboratory 411 
Animals, US National Research Council, 2011). The study was approved by the 412 
Italian Ministry of Health (approval n. 88/2013-B, issued on the 08/04/2013). All 413 
efforts were made to minimize the number of animals used and their suffering. Mice 414 
were randomized based on sex, age and weight. The sample size was chosen on the 415 
basis of past experience on tumor models in order to detect differences of at least 416 
20% between the groups. In most in vivo experiments, the investigators were 417 
unaware of the genotype of the experimental groups. 418 
 419 
 420 
Tissue collection 421 
Blood was collected from the retro-orbital plexus and by cardiac puncture as 422 
described53. Briefly, blood was collected in 2KD-EDTA spray coated tubes (BD 423 
Bioscience), washed in FACS buffer (PBS-/-, 1% BSA, 0.05 % sodium azide), red 424 
blood cells were lysed, washed again and cells were stained as indicated. Lungs 425 
were instilled with PBS for FACS analysis or 4% neutral buffer formalin for 426 
histological analysis. For FACS analysis, lungs were minced, digested for 45 min in 1 427 
mg/ml collagenase IV (Sigma) in PBS-/-, filtered with 70 μm cell strainer. Red blood 428 




tibiae. Bones were harvested, cleaned, flushed and filtered with 70 μm cell strainer. 430 
Red blood cells were lysed and cells stained as indicated below. 431 
 432 
Tumor models 433 
Tumor volume was assessed with caliper using the formula: (Length x Width x 434 
Width)/2. Tumor take in NeuT model was determinate by palpation as number of 435 
mammary tumors per mouse. For 4T1 and 4T1-66cl4 models 5 x 105 cells were 436 
injected in the mammary fat path of Balb/c mice. For lung metastasis evaluation in 437 
NeuT, 4T1 and 4T1-66cl4 model, lungs were instilled and fixed for 24 h with 4% 438 
neutral buffered formalin, routinely processed for paraffin embedding, sectioned at 4 439 
μm thickness, and stained with hematoxylin and eosin. Sections were evaluated in a 440 
blinded fashion under a light microscope. Lung metastasis in NeuT, 4T1 and 4T1-441 
66cl4 models were classified according to their size into: small (<30 neoplastic cells), 442 
medium (30–300 neoplastic cells), and large (>300 neoplastic cells). A total 443 
metastatic score was then calculated for each lung as follows: number of small 444 
metastases*1 + number of medium metastases*3 + number of large metastasis*5. 445 
Representative images were acquired with Slide Scanner VS120 dotSlide (Olympus) 446 
and analyzed with ImageJ. The melanoma cell line B16F10 (2 x 105 cells) was 447 
injected i.v. in C57BL/6 mice and metastases were macroscopically counted as dark 448 
nodules on the lung surface. For all the models, metastatic ratio was calculated as 449 
ratio of metastasis in Ackr2-/- or depleted mice compared to indicated control mice. 450 
For monocyte depletion, mice were treated with 100 μg of α-CD115 antibody (clone 451 
AFS98, Bioxcell) the day before 2 x 105 B16-F10 injection and every two days for the 452 
entire duration of the experiment. For neutrophils depletion, mice were treated with 453 
200 μg of α-Ly6G antibody (clone 1A8, Bioxcell) the day before 2 x 105 B16-F10 454 
injection and with 100 μg every three days for the entire duration of the experiment. 455 
For B cell depletion, mice were treated with 250 μg of α-CD20 (clone 5D2, 456 
Genentech Inc.) three days before 2 x 105 B16-F10 injection. For adoptive transfer 457 
experiments, neutrophils were isolated from WT and Ackr2-/- BM using the Mouse 458 
Neutrophil Isolation Kit (Miltenyi Biotec) and an autoMACS Pro separator (Miltenyi 459 
Biotec). Cell purity was assessed by flow cytometry (CD45, CD11b, Ly6G) and used 460 
only if neutrophils were ≥ 95% on CD45+ cells. For B16F10 model, recipient WT mice 461 
were injected i.v. with 5 x 106 WT or Ackr2-/- neutrophils every 3 days for the entire 462 




were injected i.v. with 2 x 106 CD45.2 WT or Ackr2-/- neutrophils 15 minutes before 464 
CCL3L1 (R&D) injection and after 1 hour lung and blood were collected and 465 
leukocytes counted by flow cytometry. 466 
 467 
Immunohistochemistry 468 
Serial 4 μm formalin-fixed and paraffin-embedded lung sections were deparaffinized 469 
and underwent heat-induced epitope retrieval with pressure cooker. Endogenous 470 
peroxidase activity was blocked by incubating sections in 3% H2O2 for 15 min. Slides 471 
were rinsed and treated with Rodent Block M (Biocare Medical) for 30 min to reduce 472 
nonspecific background staining and then incubated for 1 h at room temperature with 473 
Ly6G antibody (1:200; clone 1A8; BD Bioscience), Sections were incubated for 30 474 
min with Rat on Mouse HRP-Polymer kit (Biocare Medical). The immunoreaction was 475 
visualized with 3,3’-diaminobenzidine (Peroxidase DAB Substrate Kit, Vector 476 
Laboratories) substrate and sections were counterstained with Mayer’s haematoxylin. 477 
Negative immunohistochemical controls for each sample were prepared by replacing 478 
the primary antibody with normal serum. Positive control sections were included in 479 
each immunolabeling assay. Tissues were dehydrated with ethanol, mounted with 480 
Eukitt and acquired with an Olympus BX61 virtual slide scanning system using Cell^F 481 
software (Olympus). In each section 10 independent field of view were acquired. To 482 
evaluate the extent of granulocytes infiltration in the lung parenchyma, the 483 
percentage of Ly6G-positive area was analyzed with Image-Pro Analyzer 7.0 (Media 484 
Cybernetics) software. Representative images were generated using the ImageJ 485 
analysis program (http://rsb.info.nih.gov/ij/). 486 
 487 
Flow cytometry analysis 488 
Flow cytometry analysis were performed as previously described53. To exclude death 489 
cells from analysis, cells were stained with Violet dead cell stain kit (Thermo Fisher). 490 
Single cell suspension was stained with antibodies listed in Supplementary Table 1 491 
and related isotype. All antibodies were purchased from BD Bioscience, BioLegend, 492 
eBioscience or AbD Serotec. Flow cytometry data were acquired using a FACSCanto 493 
II (BD Bioscience) and LSR Fortessa (BD Bioscience) and data were analyzed with 494 
FACS Diva (BD Bioscience) and representative images were generated with FlowJo 495 
Software (Tree Star). To analyze ROS production, neutrophils were stained with 5 496 




FBS. Staining was blocked on ice, red blood cells were lysed, and neutrophils 498 
analyzed by flow cytometry within 2 h from the staining. Where indicated, mice were 499 
injected with 500 μg of Click-it EdU Plus (Thermo Fisher) resuspended in PBS. 500 
Femurs were harvested two hours after injection for hematopoietic progenitor 501 
analysis. For neutrophil analysis blood was collected 48 and 72 hours after injection. 502 
Staining was performed according to manufacturer instruction. The absolute number 503 
was determined by using TruCount beads (BD Biosciences) according to the 504 
manufacturer instructions. Cell sorting was performed using a FACSAria III (BD 505 
Bioscience). 506 
 507 
HPCs isolation and culture 508 
Lineage negative cells were isolated from WT and Ackr2-/- BM using LS columns and 509 
the Mouse Lineage Cell Depletion Kit (Miltenyi Biotec), according to manufacturer 510 
instruction. Negative fraction was stained with Streptavidin-PB, Sca-1, c-kit, CD34 511 
and FcγRII/III antibodies and sorted. LSK were seed (1 x 103/well) in rounded bottom 512 
96 wells plate in IMDM medium (Lonza) supplemented with 10% FCS (Sigma), 1% L-513 
glutamine (Lonza), 20 ng/ml SCF (Peprotech), 10 ng/ml IL-6 (Peprotech), 10 ng/ml 514 
IL-3 (Peprotech), as previously described54. Cells were harvested 3 and 6 days after 515 
seeding, stained and analyzed by flow cytometry. 516 
 517 
Leukocyte mobilization 518 
Mice were injected i.p. with 3 μg CCL3L1 (R&D) and after 1 h blood was collected 519 
and leukocytes counted by flow cytometry. To evaluate the percentage of monocytes 520 
in BM sinusoids, mice were injected intravenously with 1 μg Ly6C-PE antibody 2 min 521 
before the end of experiment. 522 
 523 
Generation of BM chimeras 524 
Recipient mice received gentamycin (0.8 mg/ml) in drinking water for 2 weeks 525 
starting 10 days before irradiation. WT and Ackr2-/- mice were lethally irradiated with 526 
a total dose of 900 cGy. After 2 h, mice were injected in the retro-orbital plexus with 4 527 
x 106 nucleated BM cells obtained by flushing of the cavity of a freshly dissected 528 
femur from WT or Ackr2-/- donors. Experiment were performed 16 weeks after 529 





In vitro cell killing assay 532 
Neutrophils were isolated by magnetic separation as described above from blood of 533 
14 days 4T1 tumor-bearing mice or from BM of untreated mice and seeded (1 x 534 
105/well) in a 96 wells plate in which, 4 hours before, 5 x 103 4T1-luc cells were 535 
plated in Optimem (Thermo Fisher) + 0.5% FBS. Cells were incubated overnight in 536 
presence of Apocynin 100 μM (Sigma) or DMSO control. Firefly luciferase activity 537 
was detected with luciferase assay system (Promega) and Synergy H2 (Biotek). Cell 538 
killing was calculated as percentage of tumor lysis by the following formula: % cell 539 
killing = (1 - [luminescence of samples with neutrophils] / [luminescence of samples 540 
in medium]) x 100.  541 
 542 
Transcript analysis by quantitative PCR (qPCR) 543 
Total RNA was extracted from HPCs with miRNA easy Mini kit (Qiagen). Reverse 544 
transcription was done using High Capacity cDNA Reverse Transcription Kit (Applied 545 
Biosystems). Quantitative PCR was performed with TaqMan Gene Expression 546 
Assays (Thermo Fisher) in a 7900 HT Fast Real-Time PCR System (Applied 547 
Biosystems) with probes listed in Supplementary Table 2. Total RNA was extracted 548 
from HL-60 cell and neutrophils using the TRIzol reagent (Thermo Fisher). Reverse 549 
transcription was done using High Capacity cDNA Reverse Transcription Kit (Applied 550 
Biosystems). Quantitative PCR was performed with TaqMan Gene Expression 551 
Assays in a CFX Connect Real-Time PCR Detection System (BioRad) with probes 552 
listed in Table S2. Relative mRNA expression was determined by using the 2^-ΔCt 553 
method, and normalized to the expression of the housekeeping gene β-actin or 554 
Gapdh. 555 
 556 
Statistical analysis 557 
Data are represented as mean. In all figures sample variation is shown as SD. P 558 
value was generated using the unpaired t test after normality test and F test to 559 
exclude difference in the variance between groups (GraphPad Prism 5). * = p < 0.05, 560 
** = p < 0.01, *** = p < 0.001, ns = not statistically different. 561 
 562 
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FIGURE LEGENDS 711 
Figure 1: Ackr2-/- mice are protected from lung metastasis 712 
a) NeuT/Ackr2+/+ (white squares) and NeuT/Ackr2-/- (black squares) mice were 713 
evaluated for tumor growth calculated as described in the Materials and Methods 714 
section (n = 42 for NeuT/Ackr2+/+ and 23 for NeuT/Ackr2-/- mice). b) Representative 715 
images of hematoxylin and eosin staining of NeuT/Ackr2+/+ and NeuT/Ackr2-/- lungs 716 
at 25 weeks of age. Magnification: 10X. Scale bar: 3 mm. c) Metastatic ratio of 717 
NeuT/Ackr2+/+ (white column) and NeuT/Ackr2-/- (black column) mice, calculated as 718 
described in the Materials and Methods section (n = 26 and NeuT/Ackr2+/+ and 16 for 719 
NeuT/Ackr2-/- mice, respectively). d) Tumor volume in WT (white symbols) and Ackr2-720 
/- (black symbols) mice injected orthotopically with 4T1 cells. (n = 14 for WT and 13 721 
for Ackr2-/- mice). e) Representative images of hematoxylin and eosin staining of WT 722 
and Ackr2-/- lungs at day 28 after 4T1 cell injection. Magnification: 10X. Scale bar: 3 723 
mm. f) Metastatic ratio of WT (white columns) and Ackr2-/- (black columns) mice at 724 
day 28 after orthotopic injection of 4T1 or 4T1 66cl4 cells (n = 14 for WT and 13 for 725 
Ackr2-/- mice for 4T1, 4 for both WT and Ackr2-/- mice for 4T1 66cl4). Data are 726 
represented as mean (SD). p value was generated using the unpaired t test. * = p < 727 
0.05, ** = p < 0.01, *** = p < 0.001, ns = not statistically different. 728 
Figure 2: Protection from metastasis in Ackr2-/- mice is associated with 729 
increased numbers of monocytes and neutrophils in blood and lungs 730 
a) Absolute number of circulating inflammatory monocytes (CD45+/CD11b+/Ly6Chi) 731 
and b) neutrophils (CD45+/CD11b+/Ly6G+) in NeuT/Ackr2+/+ (white squares), and 732 
NeuT/Ackr2-/- (black squares), Balb/c WT (white triangles) and Ackr2-/- (black 733 
triangles) mice (n = 9 for NeuT/Ackr2+/+ and 7 for NeuT/Ackr2-/, 3 for both WT and 734 
Ackr2-/- at 10 and 15 weeks, 6 for NeuT/Ackr2+/+ and 5 for NeuT/Ackr2-/, 5 for both 735 
WT and Ackr2-/- at 25 weeks). c) Absolute number of neutrophils, inflammatory 736 
monocytes, alveolar (CD11blow/F4/80+/Ly6Cint/CD11c+/Ly6G-) and interstitial 737 
macrophages (CD11b+/F4/80int/Ly6C-/CD11c-/Ly6G-) in the lungs of NeuT/Ackr2+/+ 738 
(white columns) and NeuT/Ackr2-/- (black columns) mice at 15 weeks of age (n = 12 739 
for NeuT/Ackr2+/+ and 6 for NeuT/Ackr2-/- mice). d) Representative 740 
immunohistochemical images of Ly6G staining in NeuT/Ackr2+/+ and NeuT/Ackr2-/- 741 
lungs at 25 weeks of age. Magnification: 20X. Scale bar: 100 μm. e) Quantification of 742 




(n = 9 for NeuT/Ackr2+/+ and 8 for NeuT/Ackr2-/- mice, respectively). f) Absolute 744 
number of neutrophils and inflammatory monocytes in the BM of WT (white columns) 745 
and Ackr2-/- (black columns) mice on day 14 after orthotopic injection of 4T1 cells (n = 746 
4 for both WT and Ackr2-/- mice). Data are represented as mean (SD). p value was 747 
generated using the unpaired t test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 748 
 749 
Figure 3: Hematopoietic expression of ACKR2 increases monocyte and 750 
neutrophil mobilization 751 
Absolute number of inflammatory monocytes (a) and neutrophils (b) in the blood of 752 
C57BL/6J WT or Ackr2-/- mice 1 h after i.p. injection of CCL3L1 or vehicle (n = 11 for 753 
WT/PBS and 8 for Ackr2-/-/PBS, 12 for WT/CCL3L1 and 10 for Ackr2-/-/CCL3L1 for 754 
monocytes; n = 8 for both WT/PBS and Ackr2-/-/PBS, 7 for WT/CCL3L1 and 5 for 755 
Ackr2-/-/CCL3L1 for neutrophils). Percentage of monocytes (c) and neutrophils (d) in 756 
the BM of the indicated mice 1 hour after CCL3L1 or vehicle i.p. injection (n = 19 for 757 
WT/PBS and 15 for Ackr2-/-/PBS, 4 for both WT/CCL3L1 and Ackr2-/-/CCL3L1 for 758 
monocytes; n = 12 for both WT/PBS and Ackr2-/-/PBS, 7 for both WT/CCL3L1 and 759 
Ackr2-/-/CCL3L1 for neutrophils). Absolute number of inflammatory monocytes (e) 760 
and neutrophils (f) in WT and Ackr2-/- mice reconstituted with either WT (white 761 
columns) or Ackr2-/- BM (black columns) after i.p. injection of CCL3L1 (n = 3 for both 762 
WT and Ackr2-/- mice). Data are represented as mean (SD). p value was generated 763 
using the unpaired t test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 764 
 765 
Figure 4: Ackr2-/- neutrophils are responsible of metastasis protection 766 
a) Metastatic ratio of C57BL/6J WT and Ackr2-/- mice 10 days after i.v. injection of 767 
B16-F10 cells (n = 14 for WT and 8 for Ackr2-/-, sum of two independent 768 
experiments). b) Metastatic ratio of C57BL/6J WT and Ackr2-/- mice, treated with 769 
isotype IgG or with α-Ly6G, 10 days after i.v. injection of B16-F10 cells (n = 6 for 770 
WT/Isotype, 5 for WT/α-Ly6G, Ackr2-/-/Isotype and Ackr2-/-/α-Ly6G) c) Metastatic 771 
ratio of Balb/c WT and Ackr2-/- mice, treated with isotype IgG or α-Ly6G antibody, 28 772 
days after orthotopic injection of 4T1 cells (n = 3 for WT/Isotype, WT/α-Ly6G and 773 
Ackr2-/-/α-Ly6G, 5 for Ackr2-/-/Isotype). d) Metastatic ratio in WT mice 10 days after 774 
i.v. injection of B16-F10 cells and adoptive transfer of WT (white dots) or Ackr2-/- 775 
neutrophils (black dots) or PBS (grey dots). Representative images of excised lungs 776 




neutrophils). Data are represented as mean (SD). p value was generated using the 778 
unpaired t test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 779 
 780 
Figure 5: Ackr2-/- neutrophils have increased tumor-killing activity and 781 
expression of inflammatory CC chemokine receptors 782 
a) MFI of CellROX emission by WT and Ackr2-/- neutrophils. Data are normalized on 783 
MFI of WT neutrophils (n = 9 for WT and 5 for Ackr2-/-). b) qPCR analysis of 784 
chemokine receptors and c) activation markers in FACS sorted neutrophils taken 785 
from unchallenged WT (white columns) and Ackr2-/- (black columns) mice (n = 4 for 786 
both WT and Ackr2-/- mice, two independent experiments). Data are relative to Gapdh 787 
expression. d) Percentage of WT and Ackr2-/- CD45.2 neutrophils on total CD45.2 788 
transferred neutrophils in the lungs of WT CD45.1 hosts and e) absolute number of 789 
circulating WT and Ackr2-/- CD45.2 neutrophils after one hour from adoptive transfer 790 
in CD45.1 hosts and i.p. injection of CCL3L1 (n = 3 recipient for each group). f) 791 
CellROX MFI in WT (white columns) and Ackr2-/- (black columns) neutrophils 792 
preincubated with PBS or LPS (100 ng/ml, 20 min) and stimulated with CCL2 (500 793 
ng/ml, 30 min) or PMA (50 ng/ml, 30 min). CellROX MFI was normalized on basal 794 
WT group (n = 4, two independent experiments for both WT and Ackr2-/- mice). g) 795 
4T1-luc cells killing by magnetically sorted circulating neutrophils taken from tumor-796 
bearing WT (white columns) and Ackr2-/- (black columns) mice 21 days after 4T1 797 
injection. Cells were treated with medium or LPS (100 ng/ml) + PMA (50 ng/ml). 798 
Where indicated Apocynin (100 μM) was added (n = 3, two independent experiments 799 
for both WT and Ackr2-/- mice). Data are represented as mean (SD). p value was 800 
generated using the unpaired t test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 801 
 802 
Figure 6: Ackr2 is expressed in HPCs and controls expression of CC 803 
chemokine receptors 804 
a) Schematic representation of murine hematopoietic cell differentiation b) qPCR 805 
analysis of Ackr2 expression on sorted HPCs and neutrophils taken from BM of WT 806 
mice (n = 7). c) qPCR analysis of Ccr2 and e) Cxcr4 expression on sorted HPCs 807 
taken from WT (white columns) and Ackr2-/- (black columns) mice. All qPCR data are 808 
relative to β-actin expression (n = 7 for both WT and Ackr2-/- mice). d) MFI of CCR2 809 
and f) CXCR4 expression measured by FACS analysis in HPCs taken from WT 810 




mice). g) MFI of CD11b h) Ly6G i) and Ly6C expression on FACS sorted LSK cells 812 
taken from WT (white columns) and Ackr2-/- (black columns) cultured in vitro as 813 
described in material and methods (n = 5 for WT and 7 for Ackr2-/- at 3 days, 5 for 814 
WT and 6 for Ackr2-/- at 6 days). j) qPCR analysis of CCR2, CD11b, and CXCR4 815 
expression in HL-60 cells transfected with ACKR2 (black columns) or empty vector 816 
(white columns). qPCR data are relative to GAPDH expression and normalized on 817 
mock transfected cells (n = 9 for mock and 13 for ACKR2 transfected cells, 3 818 
independent experiments). Data are represented as mean (SD). p value was 819 
generated using the unpaired t test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 820 
 826 
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(Linneg, Sca-1-, cKit+, CD34+, FcγRII/III+)
GMP
(Linneg, Sca-1-, cKit+, CD34+, FcγRII/IIIhi)
MEP
(Linneg, Sca-1-, cKit+, CD34-, FcγRII/III-)
Platelets
